Features of use of dapagliflozin in thetreatment of patients with type 2 diabetes mellitus


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Clinical studies published to date have shown that dapagliflozin is safe and effective for patients with type 2 diabetes mellitus, both as monotherapy and in combination with other oral hypoglycemic agents [9]. Recent publications summarizing the 4-year clinical experience confirms these results. Dapagliflozin is effective both at early and at later stages of type 2 diabetes mellitus.

全文:

受限制的访问

作者简介

M. Antsiferov

SBHCI “Endocrinologicla Dispensary" of Moscow Healthcare Department

MD, Prof., Chief Physician

参考

  1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 7-е изд. Сахарный диабет. 2015;18(1S):1-112.
  2. Дедов И.И., Шестакова М.В. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально-значимыми заболеваниями 2007-2012 гг.». Сахарный диабет. 2013;спецвыпуск:2-48.
  3. Meng W., Ellsworth B.A., NIrsch I., et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) Inhibitor for the treatment of type 2diabetes. J. Med. Chem. 2008;51:1145-49.
  4. Bailey C.J., Day C. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. Br. J. Diabetes Vasc. Dis. 2010;10:193-99.
  5. Santer R., Calado J. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin. J. Am. Soc. Nephrol. 2010;5:133-41.
  6. Kanai Y., Lee W.-S., You G., et al. The human kidney low affinity Na+/glucose cotransporter SGLT2: Delineation of the major renal reabsorptive mechanism for d-glucose. J. Clin. invest.1994;93:397-404.
  7. de Paoli P., Battistin S., Jus A., Reitano M., Villalta D., De Marchi S., Cecchin E., Basile A., Santini G. immunological characterization of renal glycosuria patients. Clin. Exp. immunol. 1984;56:289-94.
  8. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-49.
  9. Инструкция по медицинскому применению лекарственного препарата Форсига с учетом изменений 1-4. Регистрационное удостоверение № ЛП 002596 от 21.08.14.
  10. AZ-Мост Медицинский портал для специалистов. [Электронный ресурс], 12 сентября 2016. URL: http://www.az-most.ru/news/forxiga-new-horizon.html
  11. DeFronzo R.A., Davidson J.A., Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 2012;14(1):5-14.
  12. Kaku K., Kiyosue A., Inoue S., Ueda N., Tokudome T., Yang J., Langkilde A.M. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes. Metab. 2014;16:1102-10.
  13. Bailey C.J., Iqbal N., TJoen C., List J.F. Dapagliflozin monotherapy in drugnaive patients with diabetes: a randomized-controlled trial of lowdose range. Diabetes Obes. Metab. 2012;14:951-59.
  14. Ferrannini E., Ramos S.J., Salsali A., Tang W., List J.F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217-24.
  15. Ji L., Ma J., Li H., Mansfield T.A., T'Joen C.L., Iqbal N., et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin. Ther. 2014;36:84-100.
  16. List J.F., Woo V., Morales E., Tang W., Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-57.
  17. Kaku K., Inoue S., Matsuoka O., Kiyosue A., Azuma H., Hayashi N., et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo- ontrolled trial. Diabetes Obes. Metab. 2013;15:432-40.
  18. Bailey C.J., Gross J.L., Pieters A., Bastien A., List J.F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-33.
  19. Henry R.R., Murray A.V., Marmolejo M.H., Hennicken D., Ptaszynska A., List J.F. Dapaglifl ozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int. J. Clin. Pract. 2012;66(5):446-56.
  20. Nauck M.A., Del Prato S., Meier J.J., Duran-Garcia S., Rohwedder K., Elze M., Parikh S.J. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-22.
  21. Del Prato S., Nauck M., Duran-Garcia S., Maffei L., Rohwedder K., Theuerkauf A., Parikh S. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes. Metab. 2015;17:581-90.
  22. Nauck M.A., Del Prato S., Meier J.J., et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-22.
  23. Bolinder J., Ljunggren Ö., Johansson L., et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus nadequately controlled on metformin. Diabetes Obes. Metab. 2014;16(2):159-69.
  24. Sjöström C.D., Johansson P, Ptaszynska A., List J., Johnsson E. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab. Vasc. Dis. Res. 2015;12(5):352-58.
  25. Yavin Y., Mansfield T.A., Ptaszynska A., Johnsson K., Parikh S., Johnsson E. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther. 2016:7(1):125-37.
  26. Sonesson C., Johansson P.A., Johnsson E., Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc. Diabetol. 2016;15:37.
  27. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the incidence of Cardiovascular Events (DECLARE-TiMi58). https://clinicaltrials. gov/ct2/show/NCT01730534.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2016
##common.cookie##